Quantbot Technologies LP Ascendis Pharma A/S Transaction History

Quantbot Technologies LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$123.45 - $159.4 $172,830 - $223,160	-1,400 Reduced 26.42%	3,900 $589,000
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $456,329 - $675,008	5,300 New	5,300 $667,000
Q4 2021 Feb 11, 2022	SELL	$127.1 - $169.66 $470,270 - $627,742	-3,700 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$112.67 - $176.92 $416,879 - $654,604	3,700 New	3,700 $589,000
Q4 2020 Feb 12, 2021	SELL	$151.2 - $182.76 $30,239 - $36,552	-200 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$134.29 - $154.32 $26,858 - $30,864	200 New	200 $30,000
Q4 2019 Feb 10, 2020	SELL	$91.45 - $139.12 $27,435 - $41,736	-300 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$95.8 - $118.9 $28,740 - $35,670	300 New	300 $28,000
Q3 2018 Nov 13, 2018	SELL	$63.77 - $76.28 $114,084 - $136,464	-1,789 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$58.55 - $73.92 $88,059 - $111,175	-1,504 Reduced 45.67%	1,789 $119,000
Q1 2018 May 11, 2018	BUY	$38.98 - $68.04 $128,361 - $224,055	3,293 New	3,293 $215,000

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.